Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
1. October 2024
1 min to read

Time for a Diagnostic Paradigm Shift From STEMI/​NSTEMI to OMI/​NOMI (DIFOCCULT-3)

Summary

DIFOCCULT-3 is a randomized controlled study actively enrolling patients across 23 sites in Turkey. It evaluates AI-assisted ECG interpretation in detecting high-risk heart attack patterns.

By comparing traditional STEMI/NSTEMI classification with an occlusion/non-occlusion model, the trial aims to improve acute coronary blockage detection. The primary composite endpoint includes all-cause mortality and all-cause re-hospitalization at 1-year follow-up, assessing its impact on long-term patient outcomes.

Study DesignRandomized Controlled Trial (RCT)
StatusEnrolling patients
Countries / Sites1 (Turkey) / 23
Study StartOctober 1, 2024
Primary Completion (estimated)October 1, 2025
Enrollment (target)5,000
clinicaltrials.gov ID NCT06570759

Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

Artificial intelligence-enhanced ECG detection of acute coronary occlusion in chest pain patients with ST-elevation in lead aVR – A direct comparison to conventional ECG criteria

In a single‑centre retrospective study of 145 consecutive emergency‑department patients whose first ECG showed ≥1 mm ST‑elevation in lead aVR, investigators compared conventional electrocardiographic rules with a deep‑learning classifier (PMcardio “Queen of Hearts”) for recognising an acute coronary occlusion (ACO). Angiography and biomarker adjudication proved ACO in 19 patients (13 %). At an optimised probability threshold, the AI system achieved an area‑under‑the‑ROC curve of 0.918, detected 63 % of occlusions, and—crucially—generated no false‑positive calls in the 54‑patient rule‑out subgroup. By contrast, classic STEMI millimetre criteria identified only one in four occlusions and would have prompted between four and fourteen unnecessary emergency catheterisations.

AI-enhanced recognition of occlusions in acute coronary syndrome (AERO-ACS): a retrospective study

In a one‑year, single‑centre cohort of 217 cath‑lab patients (72 STEMI, 145 NSTEMI), the AERO‑ACS study tested PMcardio’s AI ECG against traditional ST‑elevation rules for detecting angiographic occlusion‑MI. The algorithm matched STEMI sensitivity (86.5 % vs 83.3 %) while raising specificity to 82.2 % (vs 66.0 %), achieved 100 % sensitivity in STEMI cases, and flagged occlusions linked to a 12‑fold higher in‑hospital mortality risk—suggesting more accurate triage with fewer unnecessary activations.

Join over 100,000 healthcare professionals who are already taking advantage of AI